Inhibition of HSC70 alleviates hypertrophic cardiomyopathy pathology in human induced pluripotent stem cell-derived cardiomyocytes with a MYBPC3 mutation

Clin Transl Med. 2021 Dec;11(12):e647. doi: 10.1002/ctm2.647.

Authors

Hangyuan Qiu¹, Yaxun Sun¹, Ziwei Pan^{2

3}, Jingjun Zhou^{2

3}, Hongkun Wang^{2

3}, Xiaochen Wang^{2

3}, Dongsheng Cai¹, Guosheng Fu¹, Tingyu Gong^{2

3}, Chenyang Jiang¹, Ping Liang^{2

3}

Affiliations

¹ Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
³ Institute of Translational Medicine, Zhejiang University, Hangzhou, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Cardiomyopathy, Hypertrophic / drug therapy*
Cardiomyopathy, Hypertrophic / physiopathology
Carrier Proteins / genetics*
HSC70 Heat-Shock Proteins / antagonists & inhibitors*
HSC70 Heat-Shock Proteins / therapeutic use
Humans
Induced Pluripotent Stem Cells / metabolism
Myocytes, Cardiac / metabolism*
Myocytes, Cardiac / physiology

Substances

Carrier Proteins
HSC70 Heat-Shock Proteins
myosin-binding protein C

Grants and funding